Silence Therapeutics plc files 10-Q

Silence Therapeutics plc reported a net loss of $14.96 million for the first quarter of 2026, a decrease from the $28.53 million net loss in the same period of 2025, driven by lower research and development expenses. The company believes its current cash and investments are sufficient to fund operations into 2028, but acknowledges the need for future funding.